These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 789783)

  • 21. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
    Yang YL; Li SY; Cheng HH; Lo HJ;
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adriamycin alters the expression of drug efflux pumps and confers amphotericin B tolerance in Candida albicans.
    O'Keeffe J; Kavanagh K
    Anticancer Res; 2004; 24(2A):405-8. PubMed ID: 15152937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth.
    Gale EF; Johnson AM; Kerridge D; Koh TY
    J Gen Microbiol; 1975 Mar; 87(1):20-36. PubMed ID: 1094096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of amphotericin B-induced endothelial cell injury.
    Cutaia M; Bullard SR; Rudio K; Rounds S
    J Lab Clin Med; 1993 Feb; 121(2):244-56. PubMed ID: 8381844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
    Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction of amphotericin B methyl ester with protoplasts of Candida albicans.
    Kerridge D; Koh TY; Johnson AM
    J Gen Microbiol; 1976 Sep; 96(1):117-23. PubMed ID: 789813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms.
    DiDone L; Oga D; Krysan DJ
    Yeast; 2011 Aug; 28(8):561-8. PubMed ID: 21674619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurements of antifungal levels in corneal tissue: a simplified bioassay for amphotericin B.
    Williams TE; O'Day DM; Head WS; Robinson RD
    Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):538-40. PubMed ID: 2265769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An internally-standardized assay for amphotericin B in tissues and plasma.
    Mayhew JW; Fiore C; Murray T; Barza M
    J Chromatogr; 1983 May; 274():271-9. PubMed ID: 6874828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of antifungal combinations against Candida albicans biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
    J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay.
    Ordóñez JV; Wehman NM
    Cytometry; 1995 Jun; 22(2):154-7. PubMed ID: 7587748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans.
    Khan MS; Malik A; Ahmad I
    Med Mycol; 2012 Jan; 50(1):33-42. PubMed ID: 21756200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong correlation between the antifungal effect of amphotericin B and its inhibitory action on germ-tube formation in a Candida albicans URA⁺ strain.
    Guirao-Abad JP; González-Párraga P; Argüelles JC
    Int Microbiol; 2015 Mar; 18(1):25-31. PubMed ID: 26415664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans.
    Geraghty P; Kavanagh K
    J Pharm Pharmacol; 2003 Feb; 55(2):179-84. PubMed ID: 12631409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
    De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
    J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated 86Rb+ (K+) release from the cytotoxic T lymphocyte is a physiologic event associated with delivery of the lethal hit.
    Russell JH; Dobos CB
    J Immunol; 1983 Sep; 131(3):1138-41. PubMed ID: 6604088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    Valentín A; Cantón E; Pemán J; Fernandez-Rivero ME; Tormo-Mas MA; Martínez JP
    J Antimicrob Chemother; 2016 Dec; 71(12):3449-3452. PubMed ID: 27543657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Spectrophotometric analysis of amphotericin B in technological objects].
    Bershteĭn IIa; Vlasenko AIu; Bershteĭn EM; Vekshin GA
    Antibiotiki; 1984 Jan; 29(1):19-24. PubMed ID: 6696398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.
    El-Azizi M; Farag N; Khardori N
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():21. PubMed ID: 25885806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.
    Ludwig DB; de Camargo LEA; Khalil NM; Auler ME; Mainardes RM
    Mycopathologia; 2018 Aug; 183(4):659-668. PubMed ID: 29497926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.